Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1996 Jan;60(1):2–5. doi: 10.1136/jnnp.60.1.2

Management of primary malignant brain tumours.

I R Whittle
PMCID: PMC486179  PMID: 8558144

Full text

PDF
2

Images in this article

5Image
on p.5

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aiken R. D. Quality-of-life issues in patients with malignant gliomas. Semin Oncol. 1994 Apr;21(2):273–275. [PubMed] [Google Scholar]
  2. Ammirati M., Vick N., Liao Y. L., Ciric I., Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery. 1987 Aug;21(2):201–206. doi: 10.1227/00006123-198708000-00012. [DOI] [PubMed] [Google Scholar]
  3. Black P. M., Ronner S. F. Cortical mapping for defining the limits of tumor resection. Neurosurgery. 1987 Jun;20(6):914–919. doi: 10.1227/00006123-198706000-00016. [DOI] [PubMed] [Google Scholar]
  4. Blasberg R. G., Groothuis D. R. Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Semin Oncol. 1986 Mar;13(1):70–82. [PubMed] [Google Scholar]
  5. Bleehen N. M., Freedman L. S., Stenning S. P. A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party. Int J Radiat Oncol Biol Phys. 1989 Apr;16(4):1077–1081. doi: 10.1016/0360-3016(89)90920-6. [DOI] [PubMed] [Google Scholar]
  6. Brem H., Piantadosi S., Burger P. C., Walker M., Selker R., Vick N. A., Black K., Sisti M., Brem S., Mohr G. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995 Apr 22;345(8956):1008–1012. doi: 10.1016/s0140-6736(95)90755-6. [DOI] [PubMed] [Google Scholar]
  7. Burger P. C., Vogel F. S., Green S. B., Strike T. A. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer. 1985 Sep 1;56(5):1106–1111. doi: 10.1002/1097-0142(19850901)56:5<1106::aid-cncr2820560525>3.0.co;2-2. [DOI] [PubMed] [Google Scholar]
  8. Cairncross G., Macdonald D., Ludwin S., Lee D., Cascino T., Buckner J., Fulton D., Dropcho E., Stewart D., Schold C., Jr Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994 Oct;12(10):2013–2021. doi: 10.1200/JCO.1994.12.10.2013. [DOI] [PubMed] [Google Scholar]
  9. Cairncross J. G., Laperriere N. J. Low-grade glioma. To treat or not to treat? Arch Neurol. 1989 Nov;46(11):1238–1239. doi: 10.1001/archneur.1989.00520470106035. [DOI] [PubMed] [Google Scholar]
  10. Chamberlain M. C., Murovic J. A., Levin V. A. Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology. 1988 Sep;38(9):1371–1374. doi: 10.1212/wnl.38.9.1371. [DOI] [PubMed] [Google Scholar]
  11. Choksey M. S., Valentine A., Shawdon H., Freer C. E., Lindsay K. W. Computed tomography in the diagnosis of malignant brain tumours: do all patients require biopsy? J Neurol Neurosurg Psychiatry. 1989 Jul;52(7):821–825. doi: 10.1136/jnnp.52.7.821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Coffey R. J., Lunsford L. D., Taylor F. H. Survival after stereotactic biopsy of malignant gliomas. Neurosurgery. 1988 Mar;22(3):465–473. doi: 10.1227/00006123-198803000-00003. [DOI] [PubMed] [Google Scholar]
  13. Culver K. W., Ram Z., Wallbridge S., Ishii H., Oldfield E. H., Blaese R. M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 1992 Jun 12;256(5063):1550–1552. doi: 10.1126/science.1317968. [DOI] [PubMed] [Google Scholar]
  14. Dropcho E. J., Soong S. J. Steroid-induced weakness in patients with primary brain tumors. Neurology. 1991 Aug;41(8):1235–1239. doi: 10.1212/wnl.41.8.1235. [DOI] [PubMed] [Google Scholar]
  15. Fine H. A. The basis for current treatment recommendations for malignant gliomas. J Neurooncol. 1994;20(2):111–120. doi: 10.1007/BF01052722. [DOI] [PubMed] [Google Scholar]
  16. Gregor A., Rampling R., Aapro M., Malmström P., Whittle I. R., Rye R., Stewart M., Sellar R., Demierre B., Ironside J. W. Phase II study of tauromustine in malignant glioma. Eur J Cancer. 1992;28A(12):1959–1962. doi: 10.1016/0959-8049(92)90236-u. [DOI] [PubMed] [Google Scholar]
  17. HITCHCOCK E., SATO R. TREATMENT OF MALIGNANT GLIOMATA. J Neurosurg. 1964 Jun;21:497–505. doi: 10.3171/jns.1964.21.6.0497. [DOI] [PubMed] [Google Scholar]
  18. Jeremic B., Grujicic D., Antunovic V., Djuric L., Stojanovic M., Shibamoto Y. Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol. 1994;21(2):177–185. doi: 10.1007/BF01052902. [DOI] [PubMed] [Google Scholar]
  19. Loew F., Papavero L. The intraarterial route of drug delivery in the chemotherapy of malignant brain tumours. Adv Tech Stand Neurosurg. 1988;16:51–79. doi: 10.1007/978-3-7091-6954-4_2. [DOI] [PubMed] [Google Scholar]
  20. Mackworth N., Fobair P., Prados M. D. Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores. J Neurooncol. 1992 Nov;14(3):243–253. doi: 10.1007/BF00172600. [DOI] [PubMed] [Google Scholar]
  21. Masciopinto J. E., Levin A. B., Mehta M. P., Rhode B. S. Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg. 1995 Apr;82(4):530–535. doi: 10.3171/jns.1995.82.4.0530. [DOI] [PubMed] [Google Scholar]
  22. Nelson D. F., Nelson J. S., Davis D. R., Chang C. H., Griffin T. W., Pajak T. F. Survival and prognosis of patients with astrocytoma with atypical or anaplastic features. J Neurooncol. 1985;3(2):99–103. doi: 10.1007/BF02228884. [DOI] [PubMed] [Google Scholar]
  23. Nitta T., Sato K., Yagita H., Okumura K., Ishii S. Preliminary trial of specific targeting therapy against malignant glioma. Lancet. 1990 Feb 17;335(8686):368–371. doi: 10.1016/0140-6736(90)90205-j. [DOI] [PubMed] [Google Scholar]
  24. Oldfield E. H., Ram Z., Culver K. W., Blaese R. M., DeVroom H. L., Anderson W. F. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther. 1993 Feb;4(1):39–69. doi: 10.1089/hum.1993.4.1-39. [DOI] [PubMed] [Google Scholar]
  25. Petersdorf S. H., Livingston R. B. High dose chemotherapy for the treatment of malignant brain tumors. J Neurooncol. 1994;20(2):155–163. doi: 10.1007/BF01052725. [DOI] [PubMed] [Google Scholar]
  26. Sandeman D. R., Patel N., Chandler C., Nelson R. J., Coakham H. B., Griffith H. B. Advances in image-directed neurosurgery: preliminary experience with the ISG Viewing Wand compared with the Leksell G frame. Br J Neurosurg. 1994;8(5):529–544. doi: 10.3109/02688699409002945. [DOI] [PubMed] [Google Scholar]
  27. Sariban E., Kohn K. W., Zlotogorski C., Laurent G., D'Incalci M., Day R., 3rd, Smith B. H., Kornblith P. L., Erickson L. C. DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone. Cancer Res. 1987 Aug 1;47(15):3988–3994. [PubMed] [Google Scholar]
  28. Seitz R. J., Wechsler W. Immunohistochemical demonstration of serum proteins in human cerebral gliomas. Acta Neuropathol. 1987;73(2):145–152. doi: 10.1007/BF00693780. [DOI] [PubMed] [Google Scholar]
  29. Selby R. The surgical treatment of cerebral glioblastoma multiforme: an historical review. J Neurooncol. 1994;18(3):175–182. doi: 10.1007/BF01328951. [DOI] [PubMed] [Google Scholar]
  30. Shapiro W. R. Therapy of adult malignant brain tumors: what have the clinical trials taught us? Semin Oncol. 1986 Mar;13(1):38–45. [PubMed] [Google Scholar]
  31. Stenning S. P., Freedman L. S., Bleehen N. M. An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer. 1987 Jul;56(1):89–90. doi: 10.1038/bjc.1987.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Thomas D. G., Nouby R. M. Experience in 300 cases of CT-directed stereotactic surgery for lesion biopsy and aspiration of haematoma. Br J Neurosurg. 1989;3(3):321–325. doi: 10.3109/02688698909002810. [DOI] [PubMed] [Google Scholar]
  33. Thorgeirsson U. P., Lindsay C. K., Cottam D. W., Gomez D. E. Tumor invasion, proteolysis, and angiogenesis. J Neurooncol. 1994;18(2):89–103. doi: 10.1007/BF01050415. [DOI] [PubMed] [Google Scholar]
  34. Whittle I. R., Denholm S. W., Gregor A. Management of patients aged over 60 years with supratentorial glioma: lessons from an audit. Surg Neurol. 1991 Aug;36(2):106–111. doi: 10.1016/0090-3019(91)90227-z. [DOI] [PubMed] [Google Scholar]
  35. Zentner J., Hufnagel A., Wolf H. K., Ostertun B., Behrens E., Campos M. G., Solymosi L., Elger C. E., Wiestler O. D., Schramm J. Surgical treatment of temporal lobe epilepsy: clinical, radiological, and histopathological findings in 178 patients. J Neurol Neurosurg Psychiatry. 1995 Jun;58(6):666–673. doi: 10.1136/jnnp.58.6.666. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES